# Quality Review: Doxorubicin Resistance Correlation Report

**Report Under Review:** `/home/donbr/ai2026/lifesciences-deepagents/output/cqs/doxorubicin-resistance-correlation-report.md`

**Competency Question:** "Using existing clinical trial data, what is the correlation between pre-clinical findings on Doxorubicin resistance mechanisms and the actual disease outcomes observed in patients?"

**Reviewer Assessment Date:** 2026-02-07

---

## Summary Verdict: PARTIAL

The report is substantive, well-organized, and genuinely attempts to answer the competency question by correlating preclinical resistance mechanisms with clinical trial evidence. It demonstrates strong entity resolution and reasonable source attribution. However, it falls short on several Fuzzy-to-Fact protocol requirements: no disease CURIE was resolved, the LOCATE-then-RETRIEVE discipline is not explicitly demonstrated, evidence grading uses a simplified scheme rather than the claim-level numeric scoring required by the reporting skill, and some claims carry hallucination risk. The report also uses a custom structure rather than selecting from the 7 defined report templates.

**Overall Score: 6/10 dimensions pass or partially pass**

---

## Dimension 1: CURIE Resolution

**Verdict: PARTIAL PASS**

**What was done well:**
- All four core genes are resolved to HGNC IDs: ABCB1 (HGNC:40), BCL2 (HGNC:990), TP53 (HGNC:11998), TOP2A (HGNC:11989)
- All four proteins resolved to UniProt accessions: P08183, P10415, P04637, P11388
- STRING protein IDs provided for all four: 9606.ENSP00000478255, 9606.ENSP00000381185, 9606.ENSP00000269305, 9606.ENSP00000411532
- Chromosomal locations provided for all four genes
- Drug CURIEs partially provided: Doxorubicin (CHEMBL:53463, PubChem:CID31703), Venetoclax (CHEMBL:3137309, IUPHAR:8318), Verapamil (CHEMBL:6966, IUPHAR:2406), Tariquidar (CHEMBL:348475)

**What is missing or problematic:**
- **No disease CURIE.** The report discusses doxorubicin resistance across multiple cancer types (breast cancer, ovarian cancer, AML, DLBCL, TNBC) but none are resolved to MONDO or EFO CURIEs. This is a significant gap per the graph-builder skill requirements.
- NCT IDs use an unusual format `NCT:00001944` (with colon) rather than the standard `NCT00001944` or the Graphiti convention. The graph-builder skill specifies `NCT03312634` (no colon) for trial IDs. This inconsistency could cause issues with downstream persistence.
- Several interactor proteins mentioned in the text (CYP3A4, CYP3A5, CYP2C19, SLCO1B1, NR1I2, BIK, BAX, BAK1, BCL2L1, BCL2L11, BBC3, PMAIP1, SIRT1, RPA1, MDM2, ATM, EP300, HDAC1, CREBBP, CDK1, CCNB1, CDC20, CCNA2, BUB1, BUB1B, ASPM, MKI67) are referenced by gene symbol only, without HGNC CURIEs. The first-mention rule in the reporting skill requires both name and CURIE on first mention.
- Obatoclax, Batracylin, AZD1775, XR9576, SGI-110, KRT-232 are mentioned without ChEMBL or IUPHAR CURIEs.

---

## Dimension 2: Source Attribution

**Verdict: PARTIAL PASS**

**Sourced claims count:** Approximately 25 explicit `[Source: ...]` citations throughout the report.

**Unsourced claims count:** Approximately 15-20 factual claims lack source attribution.

**Examples of properly sourced claims:**
- `[Source: uniprot_get_protein(UniProtKB:P08183)]` for ABCB1 molecular function (line 34)
- `[Source: string_get_interactions(STRING:9606.ENSP00000478255, required_score=700)]` for ABCB1 interactions (line 38)
- `[Source: clinicaltrials_get_trial(NCT:00001944)]` for specific trial details (line 150)

**Examples of unsourced claims:**
- "Overexpression of ABCB1 leads to active efflux of doxorubicin, reducing intracellular drug concentration below cytotoxic threshold" (line 47) -- no source citation
- "Cross-resistance to other chemotherapy drugs (paclitaxel, vincristine, etoposide) occurs due to broad substrate specificity" (line 47) -- no source citation
- "Venetoclax FDA-approved for CLL/AML, demonstrating BCL2 pathway is clinically actionable" (line 236) -- no source for the FDA approval claim
- "TP53 mutations (found in >50% of cancers)" (line 108) -- statistical claim without source
- "TNBC has ~80% TP53 mutation rate" (line 250) -- statistical claim without source
- The entire "Resistance Mechanism" subsection for each gene lacks `[Source:]` tags
- Section 5.1 mentions "18/40 trials in 'doxorubicin resistance' search" (line 389) without citing which search produced this
- "No FDA-approved P-gp inhibitors despite mechanistic validation" (line 412) -- regulatory claim without source
- Section 6 (Knowledge Gaps) and Section 8 (Conclusions) are largely unsourced synthesis

The reporting skill requires: "Every factual claim must cite the tool call that produced it." The resistance mechanism descriptions, cross-mechanism clinical implications, and several statistical claims fail this requirement.

---

## Dimension 3: LOCATE to RETRIEVE Discipline

**Verdict: FAIL**

The report does not explicitly demonstrate the two-step LOCATE-then-RETRIEVE pattern required by the graph-builder skill. Specifically:

- **No LOCATE step is shown.** The report jumps directly to RETRIEVE calls (e.g., `uniprot_get_protein`, `clinicaltrials_get_trial`) without showing the prior LOCATE step (e.g., `hgnc_search_genes("ABCB1")` before `hgnc_get_gene(HGNC:40)`).
- The HGNC IDs appear as canonical identifiers but there is no `[Source: hgnc_search_genes("ABCB1")]` citation showing how HGNC:40 was resolved.
- STRING IDs are used directly in RETRIEVE calls but no `[Source: string_search_proteins("ABCB1", species=9606)]` LOCATE call is shown.
- Some trial citations use `clinicaltrials_search_trials` (a LOCATE call), but these are used directly as evidence rather than followed by `clinicaltrials_get_trial` (RETRIEVE) for each result. Trials in Section 2.3 and 2.4 cite `clinicaltrials_search_trials` as the source but include detailed trial information (status, phase, design, population, interventions, primary outcomes) that would only come from a RETRIEVE call.
- The Chain-of-Thought requirement ("Before each tool call, briefly state: 1. What information I need, 2. Which tool will provide it...") is not followed anywhere.

This is a protocol compliance failure. The graph-builder skill states: "NEVER skip LOCATE. NEVER use an ID you didn't get from a LOCATE call."

---

## Dimension 4: Disease CURIE in ENRICH Phase

**Verdict: FAIL**

No disease CURIE (MONDO or EFO) is resolved anywhere in the report. The report discusses:
- Breast cancer
- Ovarian cancer (platinum-resistant)
- AML
- DLBCL
- TNBC (triple-negative breast cancer)
- BPDCN (blastic plasmacytoid dendritic cell neoplasm)
- ALL
- CLL
- Richter's Syndrome
- MDS

None of these are resolved to MONDO/EFO identifiers. The graph-builder skill explicitly requires: "Record disease CURIE (e.g., MONDO:0007606 for FOP) for Phase 4a/4b" during Phase 2 ENRICH. This is listed as a critical output for downstream phases.

The Graphiti knowledge graph in Section 7 also lacks any disease nodes -- it has genes, compounds, and trials but no disease entities with CURIEs.

---

## Dimension 5: Open Targets Pagination

**Verdict: N/A (with concerns)**

The report does not explicitly mention using Open Targets `knownDrugs` queries. Open Targets is listed in the "Databases Accessed" section (line 531) and the drug Venetoclax has a CHEMBL ID, but there are no `[Source: opentargets_get_target(...)]` or `[Source: opentargets_get_associations(...)]` citations anywhere in the report.

This raises a secondary concern: Open Targets was listed as the PRIMARY drug discovery source in the skill definition, yet the report appears to have relied on ClinicalTrials.gov search and UniProt/STRING rather than Open Targets for drug-target data. The drug candidates (Venetoclax, Verapamil, Tariquidar, Obatoclax, XR9576) are mentioned in the context of clinical trials rather than discovered via Open Targets `knownDrugs`.

While this is not a "pagination failure," it represents a missed opportunity to use the most reliable drug discovery API.

---

## Dimension 6: Evidence Grading

**Verdict: PARTIAL PASS**

**What was done well:**
- Evidence levels L1-L4 are defined (Section 4, lines 362-366)
- Modifiers (+, neutral, -) are defined (lines 368-370)
- Each resistance mechanism is graded: ABCB1 (L4+), BCL2 (L4), TP53 (L3), TOP2A (L2-L3)
- An overall confidence assessment is provided: "HIGH (median evidence grade: L3-L4)"
- A summary correlation table is provided (lines 376-381)

**What is missing per the reporting skill:**
- **No claim-level numeric scoring.** The reporting skill requires each claim to receive a numeric score (0.00-1.00) with applied modifiers. The report uses shorthand labels (L4+, L3, L2-L3) but never computes numeric scores like 0.95 or 0.65.
- **No per-claim grading.** The grading is done per resistance mechanism (4 grades total), not per individual claim. The reporting skill states: "Grade **each claim** individually, then compute an overall report confidence."
- **No modifier application.** The modifiers are defined but never applied to specific claims. The reporting skill provides specific modifiers (Active trial: +0.10, High STRING score: +0.05, etc.) that should be computed and shown.
- **No range reported.** The reporting skill requires "Report the range (lowest to highest claim score)" -- this is missing.
- **No "Insufficient Evidence" flags** for claims below L1.
- The median computation is stated as "L3-L4" which is imprecise. The reporting skill expects a numeric median.

---

## Dimension 7: Gain-of-Function Filter

**Verdict: N/A**

Doxorubicin resistance is not a gain-of-function disease in the traditional sense (unlike FOP/ACVR1). The resistance mechanisms described are acquired alterations (ABCB1 overexpression, BCL2 overexpression, TP53 loss-of-function, TOP2A alterations). The gain-of-function filter is designed for diseases like FOP where constitutive receptor activation is the pathology, and agonists must be excluded.

This dimension does not apply to this competency question.

---

## Dimension 8: Clinical Trial Validation

**Verdict: PARTIAL PASS**

**NCT IDs present:** The report references approximately 20 distinct NCT IDs across all sections.

**Trials with explicit `clinicaltrials_get_trial` verification (RETRIEVE):**
- NCT:00001944 (line 150-151)
- NCT:00001493 (line 162-163)
- NCT:05741372 (line 174-175)
- NCT:04216524 (line 194-195)
- NCT:00933985 (line 207-208)

These 5 trials are cited with `clinicaltrials_get_trial` sources and include detailed structured data (status, phase, design, population, interventions, primary outcomes), suggesting they went through Phase 5 VALIDATE.

**Trials cited via `clinicaltrials_search_trials` only (LOCATE without RETRIEVE):**
- NCT:03984448 (line 219) -- cited via search, but includes detailed information
- NCT:04335669 (line 243-244) -- cited via search
- NCT:01748825 (line 254-255) -- cited via search

**Trials with no source citation at all:**
- NCT:03054896 (line 229)
- NCT:03319901 (line 230)
- NCT:04790903 (line 231)
- NCT:04055038 (line 393)
- NCT:01696032 (line 394)
- NCT:01170650 (line 395)
- NCT:00327171 (line 396)
- NCT:01898494 (line 265)
- NCT:07131085 (line 266)
- NCT:07372885 (line 266)
- NCT:03041688 (line 415)
- NCT:05358639 (line 444)
- NCT:00880503 (line 428)
- NCT:06619236 (line 297)

Approximately 14 NCT IDs appear without explicit verification via `clinicaltrials_get_trial`. Per the validation checklist: "Every NCT ID verified via `clinicaltrials_get_trial`." The report does not have a "Verified" column in its trial tables.

**Format concern:** NCT IDs use `NCT:XXXXXXXX` format (with colon) throughout. The standard format is `NCTXXXXXXXX` (no colon). The graph-builder skill uses bare `NCT03312634` format. This formatting inconsistency may indicate the IDs were not retrieved from ClinicalTrials.gov API responses (which would return `NCT00001944` without a colon).

**Suspicious NCT IDs:** NCT:07131085 and NCT:07372885 (line 266) have very high sequence numbers that would be unusual for completed or even active trials as of early 2026. These should be verified.

---

## Dimension 9: Completeness

**Verdict: PASS**

The report does answer the competency question. It:

1. **Identifies 4 preclinical resistance mechanisms** (ABCB1 efflux, BCL2 apoptosis evasion, TP53 mutations, TOP2A alterations) with molecular detail from UniProt and STRING.

2. **Maps each mechanism to clinical trial evidence**, providing specific NCT IDs and trial details for each.

3. **Assesses correlation strength** for each mechanism:
   - ABCB1: STRONG (3 completed trials directly targeting P-gp)
   - BCL2: STRONG (10+ trials with venetoclax)
   - TP53: MODERATE (indirect evidence from biomarker trials)
   - TOP2A: WEAK-TO-MODERATE (limited direct validation)

4. **Identifies cross-mechanism interactions** (TP53-BCL2 axis, ABCB1-CYP3A axis) that provide biological context.

5. **Addresses the gap** between preclinical knowledge and clinical translation -- noting that despite strong mechanistic evidence for P-gp, no FDA-approved P-gp inhibitors exist.

6. **Provides knowledge gaps** and future research directions.

The report structure is comprehensive: 8 major sections covering mechanisms, trials, network analysis, evidence grading, outcome patterns, knowledge gaps, graph representation, and conclusions. It genuinely engages with the "correlation" aspect of the question rather than merely listing mechanisms and trials separately.

**Minor gap:** The report could more explicitly address "actual disease outcomes observed in patients" -- most trial citations report status (COMPLETED, RECRUITING, TERMINATED) but not published outcome data (e.g., response rates, PFS, OS). This is partially addressed in Section 8.3 Limitations ("Clinical trial outcomes not yet published for many active trials").

---

## Dimension 10: Hallucination Risk

**Verdict: MEDIUM-HIGH**

Several categories of content raise hallucination concerns:

**High-risk claims (likely from training knowledge):**

1. **"TP53 mutations (found in >50% of cancers)"** (line 108) -- This is a well-known statistic but has no tool source. It should either be sourced or removed.

2. **"TNBC has ~80% TP53 mutation rate"** (line 250) -- Statistical claim without source attribution. Appears to be training knowledge.

3. **"Venetoclax FDA-approved for CLL/AML"** (lines 236, 407) -- Regulatory status claim without source. While true, the grounding rule requires tool-sourced data.

4. **Resistance mechanism descriptions** (lines 47-48, 77-78, 107-108, 138-139) -- These paragraphs describe biological mechanisms in confident prose without `[Source:]` tags. While some content may be inferable from the UniProt function text cited above, the specific claims about doxorubicin resistance (e.g., "reducing intracellular drug concentration below cytotoxic threshold," "prevents cytochrome c release and caspase activation") go beyond what UniProt typically returns.

5. **Historical context** (line 410) -- "Historical trials (1990s-2000s): Verapamil, cyclosporine, PSC-833 -> toxicity/PK interactions limited use" -- This appears to be training knowledge, not from any cited tool call.

6. **"XR9576 is a third-generation P-gp inhibitor designed to block ABCB1 without metabolic interactions seen with earlier agents (verapamil, cyclosporine)"** (line 158) -- Drug generation classification and comparative pharmacology without source.

7. **"Doxorubicin stabilizes TOP2A-DNA cleavage complexes, causing DNA double-strand breaks"** (line 139) -- Specific mechanism of action claim without source.

**Medium-risk claims:**

8. **Cross-mechanism interaction implications** (lines 314-315, 322-323, 328-329) -- Clinical implications drawn from STRING interaction data (e.g., "BCL2 inhibitors may be more effective in p53-mutant tumors") go beyond what the tool data directly supports.

9. **Section 6 Knowledge Gaps** -- While framed as gaps, some claims embed factual assertions (e.g., "SNPs in ABCB1 (e.g., C3435T) alter P-gp expression" on line 438).

The graph-builder skill's Critical Grounding Rule states: "YOU MUST NOT use your training knowledge to provide entity names, drug names, gene functions, disease associations, or clinical trial IDs. ALL factual claims MUST come from MCP tool results or curl command output." Multiple claims in this report appear to violate this rule.

---

## Score Summary

| # | Dimension | Verdict | Score |
|---|-----------|---------|-------|
| 1 | CURIE Resolution | PARTIAL PASS | Core genes/proteins resolved; diseases and many interactors unresolved |
| 2 | Source Attribution | PARTIAL PASS | ~25 sourced claims, ~15-20 unsourced |
| 3 | LOCATE-RETRIEVE Discipline | FAIL | No explicit two-step pattern shown |
| 4 | Disease CURIE in ENRICH | FAIL | No MONDO/EFO CURIEs anywhere |
| 5 | Open Targets Pagination | N/A | Open Targets not visibly used for drug discovery |
| 6 | Evidence Grading | PARTIAL PASS | Levels used but no numeric claim-level scoring |
| 7 | Gain-of-Function Filter | N/A | Not applicable to this disease |
| 8 | Clinical Trial Validation | PARTIAL PASS | 5/~20 NCT IDs verified via RETRIEVE; 14+ unverified |
| 9 | Completeness | PASS | Answers the competency question with depth |
| 10 | Hallucination Risk | MEDIUM-HIGH | Multiple unsourced mechanism descriptions and statistics |

---

## Recommendations

1. **Add disease CURIEs.** Resolve at least the primary cancer types discussed (breast cancer, AML, DLBCL, ovarian cancer) to MONDO or EFO identifiers during Phase 2 ENRICH.

2. **Show LOCATE steps.** Add `[Source: hgnc_search_genes("ABCB1")]` citations before the RETRIEVE citations. This demonstrates provenance and protocol compliance.

3. **Verify all NCT IDs.** Run `clinicaltrials_get_trial` for each of the 14+ unverified NCT IDs. Add a "Verified" column to trial tables. Pay special attention to NCT:07131085 and NCT:07372885 which have unusually high sequence numbers.

4. **Remove or source unsourced claims.** The resistance mechanism descriptions, statistical claims (">50% of cancers", "~80% TP53 mutation rate"), and FDA approval assertions need either `[Source:]` tags or removal.

5. **Implement numeric evidence grading.** Apply the 0.00-1.00 scoring system with explicit modifier calculations per the reporting skill specification. Compute and report the numeric median.

6. **Use Open Targets for drug discovery.** The skill designates Open Targets `knownDrugs` as the PRIMARY drug discovery source. The report should show `opentargets_get_target` calls for each gene's Ensembl ID.

7. **Fix NCT ID format.** Standardize to `NCT00001944` (no colon) to match ClinicalTrials.gov API output and the graph-builder skill convention.

8. **Add first-mention CURIEs for interactors.** Proteins like CYP3A4, BAX, MDM2, CDK1, etc. should include HGNC CURIEs on first mention per the reporting skill's first-mention rule.
